002644.SZ
Lanzhou Foci Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 8.18
−0.24%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
31.0x
Market Cap
CNY 4.18B
MomentumView details →
1D Return
−0.24%
YTD Return
−1.39%
RSI (14)
54.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
31.0x
Market Cap
CNY 4.18B
RSI (14)
54.9
MomentumView details →
1D Return
−0.24%
YTD Return
−1.39%
Similar companies
Latest newsMore news →
The indirect controlling shareholder of Foci Pharmaceutical changed to Gansu Pharmaceutical Group during the reporting period, while the controlling shareholder remained unchanged.18d agoFoci Pharmaceutical announced its 2026 first-half results with revenue of 440 million yuan, up 2.55% year-on-year, and net profit attributable to shareholders of 39.74 million yuan, up 32.00%.18d ago